 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular Therapeutix, Inc. NASDAQ:OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the submission of the supplemental New Drug Application sNDA to the U.S. Food and Drug Administration FDA for DEXTENZA dexamethasone ophthalmic insert 0.4 mg for intracanalicular use. If approved, this sNDA would include the treatment of ocular itc 